Flatlander schreef op 6 april 2022 01:23:
Your post has some good points. Specifically, the following point might ring true.
"I don't find the MDx market very interesting after all. They all chase each other out of the tent in rapid succession. I can imagine your fascination for the science behind it ."
About a year and a half ago I posted a link to a Diaceutics report that pointed out that MDx were being disproportionately undercompensated relative to the benefit they bring to the patient in the treatment of their cancer. The report pointed out that the EGFR test provider received only a fraction of 1% of the patients overall treatment cost compared to the pharma companies compensation of up to 50% for a targeted therapy drug.
Diaceutics Pharma Precision Medicine Readiness Report 2020, “NSCLC: An Axis for Change.”
I shared this information with the board but it might support your point that MDx investing might not make as much sense as investing where the bulk of the treatment costs are spent. In my defense I had a reason for investing in this sector despite its record for being undercompensated. I did well with my 1st three investments in the sector (Vysis, Foundation and Genomic Health). Sadly BCART has not gone that way. My other investment Novacyt has been a wash since I initially bought well, took a nice profit but re-entered the position and got caught up in the DHSC dispute.
I would point out that JnJ and Invesco (Oppenheimer) have had good track records with their historical investments also bought into the Idylla story. The intersection of MDx, personalized medicine and automation, looks to have a lot of potential for disruption but atlas BCART has not yet been able to scale in a manner that suggests they can be the disruptive player I had hoped. I still maintain they can turn it around, but all in all I wish I did not get caught up in the Idylla story when I followed GHDX to BCARTs doorstep.